Mechanism of action of the hypnotic zolpidem in vivo

被引:222
作者
Crestani, F
Martin, JR
Möhler, H
Rudolph, U
机构
[1] Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland
[2] Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland
[3] F Hoffmann La Roche & Co Ltd, Preclin Res, Div Pharma, CH-4002 Basel, Switzerland
关键词
GABA(A) receptor; zolpidem; benzodiazepines; knock-in mouse; targeted mutation;
D O I
10.1038/sj.bjp.0703717
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Zolpidem is a widely used hypnotic agent acting at the GABA(A) receptor benzodiazepine site. On recombinant receptors, zolpidem displays a high affinity to alpha1-GABA(A) receptors, an intermediate affinity to alpha (2)- and alpha (3)-GABA(A) receptors and fails to bind to alpha (5)-GABA(A) receptors. However, it is not known which receptor subtype is essential for mediating the sedative-hypnotic action in vivo. Studying alpha1(H101R) mice, which possess zolpidem-insensitive alpha (1)-GABA(A) receptors, we show that the sedative action of zolpidem is exclusively mediated by alpha (1)-GABA(A) receptors. Similarly, the activity of zolpidem against pentylenetztrazole-induced tonic convulsions is also completely mediated by alpha (1)-GABA(A) receptors. These results establish that the sedative-hypnotic and anticonvulsant activities of zolpidem are due to its action on alpha (1)-GABA(A) receptors and not on,or alpha (3)-GABA(A) receptors.
引用
收藏
页码:1251 / 1254
页数:4
相关论文
共 17 条
  • [1] PHARMACOLOGICAL PROFILE OF THE IMIDAZOPYRIDINE ZOLPIDEM AT BENZODIAZEPINE RECEPTORS AND ELECTROCORTICOGRAM IN RATS
    ARBILLA, S
    DEPOORTERE, H
    GEORGE, P
    LANGER, SZ
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1985, 330 (03) : 248 - 251
  • [2] BARTHOLINI G, 1993, IMIDAZOPYRIDINES ANX, P1
  • [3] GABA(A) receptor subtypes differentiated by their gamma-subunit variants: Prevalence, pharmacology and subunit architecture
    Benke, D
    Honer, M
    Michel, C
    Mohler, H
    [J]. NEUROPHARMACOLOGY, 1996, 35 (9-10) : 1413 - 1423
  • [4] Conover WJ, 1999, PRACTICAL NONPARAMET, P3
  • [5] DEPOORTERE H, 1986, J PHARMACOL EXP THER, V237, P649
  • [6] NOVEL ANXIOLYTICS THAT ACT AS PARTIAL AGONISTS AT BENZODIAZEPINE RECEPTORS
    HAEFELY, W
    MARTIN, JR
    SCHOCH, P
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (11) : 452 - 456
  • [7] Management of insomnia
    Kupfer, DJ
    Reynolds, CF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05) : 341 - 346
  • [8] Langer S.Z., 1992, EUR NEUROPSYCHOPHARM, V2, P232, DOI DOI 10.1016/0924-977X(92)90081-I
  • [9] SYNTHETIC NON-BENZODIAZEPINE LIGAND FOR BENZODIAZEPINE RECEPTORS - PROBE FOR INVESTIGATING NEURONAL SUBSTRATES OF ANXIETY
    LIPPA, AS
    COUPET, J
    GREENBLATT, EN
    KLEPNER, CA
    BEER, B
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1979, 11 (01) : 99 - 106
  • [10] Sedative but not anxiolytic properties of benzodiazepines ave mediated by the GABAA receptor α1 subtype
    McKernan, RM
    Rosahl, TW
    Reynolds, DS
    Sur, C
    Wafford, KA
    Atack, JR
    Farrar, S
    Myers, J
    Cook, G
    Ferris, P
    Garrett, L
    Bristow, L
    Marshall, G
    Macaulay, A
    Brown, N
    Howell, O
    Moore, KW
    Carling, RW
    Street, LJ
    Castro, JL
    Ragan, CI
    Dawson, GR
    Whiting, PJ
    [J]. NATURE NEUROSCIENCE, 2000, 3 (06) : 587 - 592